Ref. | Age | Sex | Location | Treatment | Survival |
---|---|---|---|---|---|
4 | 42 | M | Body | Symptomatic | 1 month |
4 | 67 | M | Head | Symptomatic | 1 month |
4 | 62 | M | Head | Symptomatic | 2 months |
4 | 54 | M | Head | Symptomatic | 2 months |
4 | 73 | M | Head | Symptomatic | 1 month |
5 | 45 | M | Head | Symptomatic | Not stated |
5 | 75 | M | Head | Symptomatic | Not stated |
6 | 27-60 | 3F/3M | Head | Surgery and Chemoradiotherapy | 9-173 months |
7 | 50 | F | Tail | Symptomatic | 2 weeks |
8 | 66 | M | Head | Symptomatic, polychemotherapy followed by CDDP VP-16 | 2 week |
12 | 69 | F | Head | Surgery and CDDP, VP-16 | 6 months |
13 | 62 | M | Head | CDDP, Doxorubicin, VP-16 | 2 month |
18 | 54 | M | Head | Polychemotherapy followed by CDDP, VP-16 | 50 month |
19 | 64 | F | Not stated | Carboplatin, etoposide | 56 months |
19 | 69 | M | Not stated | Carboplatin, etoposide | 14 months |
19 | 62 | M | Not stated | Carboplatin, etoposide | 9 months |
19 | 69 | M | Not stated | Carboplatin, etoposide | 18 months |
20 | 74 | M | Tail | Gemcitabin, PEGylated octreotide, 5-FU | 8 months |